JavaScript 似乎在您的浏览器中被禁用。 为了您在我们网站能获得最好的体验，建议在浏览器中打开Javascript。

若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系

EasySep™人T细胞富集试剂盒

通过免疫磁珠负选分离出无磁珠标记的人T细胞

率先评论此产品

产品号 #（选择产品）

产品号 #19051_C

通过免疫磁珠负选分离出无磁珠标记的人T细胞

产品优势

易于操作、快速，且无需分离柱
纯度高达99%
获得的活细胞无标记

产品组分包括

EasySep™ 人T细胞富集试剂盒（产品号#19051）

EasySep™ 人T细胞富集抗体混合物，1 mL
EasySep™ D Magnetic Particles磁珠，1 mL

RoboSep™ 人T细胞富集试剂盒（含过滤吸头）(产品号 #19051RF)

EasySep™ 人T细胞富集抗体混合物，1 mL
EasySep™ D Magnetic Particles磁珠， 1 mL
RoboSep™ 缓冲液（产品号#20104）
RoboSep™过滤吸头（产品号#20125）

跳到结尾的图片库

main product photo

跳转到图像库的开头

New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more

要查看实验方案所需的所有配套产品，请参阅《实验方案与技术文档》。

EasySep™ Magnet
Magnet for column-free immunomagnetic separation
EasySep™ Buffer
Cell separation buffer
Labeling Antibodies
Compatible antibodies for purity assessment of isolated cells

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

相关产品

总览

通过免疫磁珠负选，从新鲜或冻存的人外周血单个核细胞 (PBMCs) 或白细胞单采术样本中分离出高度纯化的T细胞。EasySep™技术结合单克隆抗体的特异性和无柱磁分选系统的简便性，已在发表的研究中广泛应用超过20年。

在此 EasySep™ 负选方案中，非目的细胞通过抗体复合物与磁珠标记。表面表达以下标志物的非目的细胞将被特异性去除：CD14、CD16、CD19、CD20、CD36、CD56、CD66b、CD123及GlyA。通过EasySep™磁极，将这些被磁珠标记的细胞与未被标记的目的细胞分离，接着简单的将目的细胞倾倒或吸取至一个新的试管中。完成磁珠分选后，分选得到的T细胞可直接用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。

如需更快速的细胞分选方案，我们推荐EasySep™ 人T细胞分选试剂盒（产品号 #17951），仅需8分钟即可完成分选。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现免疫磁珠细胞分选全自动化。另外，您还可以选择即用型、符合伦理来源的冷冻人外周血原代 Pan-T 细胞，这些细胞使用EasySep™ 人T细胞富集试剂盒分选得到。探索为您的实验流程优化的更多产品，包括培养基、添加剂、抗体等。

在此 EasySep™ 负选方案中，非目的细胞通过抗体复合物与磁珠标记。表面表达以下标志物的非目的细胞将被特异性去除：CD14、CD16、CD19、CD20、CD36、CD56、CD66b、CD123及GlyA。通过EasySep™磁极，将这些被磁珠标记的细胞与未被标记的目的细胞分离，接着简单的将目的细胞倾倒或吸取至一个新的试管中。完成磁珠分选后，分选得到的T细胞可直接用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。

如需更快速的细胞分选方案，我们推荐EasySep™ 人T细胞分选试剂盒（产品号 #17951），仅需8分钟即可完成分选。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现免疫磁珠细胞分选全自动化。另外，您还可以选择即用型、符合伦理来源的冷冻人外周血原代 Pan-T 细胞，这些细胞使用EasySep™ 人T细胞富集试剂盒分选得到。探索为您的实验流程优化的更多产品，包括培养基、添加剂、抗体等。

在此 EasySep™ 负选方案中，非目的细胞通过抗体复合物与磁珠标记。表面表达以下标志物的非目的细胞将被特异性去除：CD14、CD16、CD19、CD20、CD36、CD56、CD66b、CD123及GlyA。通过EasySep™磁极，将这些被磁珠标记的细胞与未被标记的目的细胞分离，接着简单的将目的细胞倾倒或吸取至一个新的试管中。完成磁珠分选后，分选得到的T细胞可直接用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。

如需更快速的细胞分选方案，我们推荐EasySep™ 人T细胞分选试剂盒（产品号 #17951），仅需8分钟即可完成分选。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现免疫磁珠细胞分选全自动化。另外，您还可以选择即用型、符合伦理来源的冷冻人外周血原代 Pan-T 细胞，这些细胞使用EasySep™ 人T细胞富集试剂盒分选得到。探索为您的实验流程优化的更多产品，包括培养基、添加剂、抗体等。

在此 EasySep™ 负选方案中，非目的细胞通过抗体复合物与磁珠标记。表面表达以下标志物的非目的细胞将被特异性去除：CD14、CD16、CD19、CD20、CD36、CD56、CD66b、CD123及GlyA。通过EasySep™磁极，将这些被磁珠标记的细胞与未被标记的目的细胞分离，接着简单的将目的细胞倾倒或吸取至一个新的试管中。完成磁珠分选后，分选得到的T细胞可直接用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。

如需更快速的细胞分选方案，我们推荐EasySep™ 人T细胞分选试剂盒（产品号 #17951），仅需8分钟即可完成分选。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现免疫磁珠细胞分选全自动化。另外，您还可以选择即用型、符合伦理来源的冷冻人外周血原代 Pan-T 细胞，这些细胞使用EasySep™ 人T细胞富集试剂盒分选得到。探索为您的实验流程优化的更多产品，包括培养基、添加剂、抗体等。

磁体兼容性
• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • Easy 50 EasySep™ Magnet (Catalog #18002) • EasyPlate™ EasySep™ Magnet (Catalog 18102) • EasyEights™ EasySep™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000)

亚型
细胞分选试剂盒

细胞类型
T 细胞

种属
人

样本来源
Leukapheresis，PBMC

筛选方法
Negative

应用
细胞分选

品牌
EasySep，RoboSep

研究领域
免疫

查看更多显示更少

实验数据

FACS Histogram Results With EasySep™ Human T Cell Enrichment Kit

Figure 1. FACS Histogram Results With EasySep™ Human T Cell Enrichment Kit

Starting with previously frozen mononuclear cells, the CD3+ cell content of the enriched fraction typically ranges from 95% - 99%.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type

Product Name

Catalog #

Lot #

Language

Document Type

Product Information Sheet

Product Name

EasySep™ Human T Cell Enrichment Kit

Catalog #

19051

Lot #

All

Language

English

Document Type

Product Information Sheet

Product Name

RoboSep™ Human T Cell Enrichment Kit with Filter Tips

Catalog #

19051RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

EasySep™ Human T Cell Enrichment Kit

Catalog #

19051

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

EasySep™ Human T Cell Enrichment Kit

Catalog #

19051

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

RoboSep™ Human T Cell Enrichment Kit with Filter Tips

Catalog #

19051RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

RoboSep™ Human T Cell Enrichment Kit with Filter Tips

Catalog #

19051RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 3

Product Name

RoboSep™ Human T Cell Enrichment Kit with Filter Tips

Catalog #

19051RF

Lot #

All

Language

English

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

Research Area

Workflow Stages

Workflow Stages for T Cell Research

Cell Activation, Expansion, and Differentiation

Cell Characterization

相关材料与文献

Can EasySep™ be used for either positive or negative selection?

Yes. The EasySep™ kits use either a negative selection approach by targeting and removing unwanted cells or a positive selection approach targeting desired cells. Depletion kits are also available for the removal of cells with a specific undesired marker (e.g. GlyA).

How does the separation work?

Magnetic particles are crosslinked to cells using Tetrameric Antibody Complexes (TAC). When placed in the EasySep™ Magnet, labeled cells migrate to the wall of the tube. The unlabeled cells are then poured off into a separate fraction.

Which columns do I use?

The EasySep™ procedure is column-free. That's right - no columns!

How can I analyze the purity of my enriched sample?

The Product Information Sheet provided with each EasySep™ kit contains detailed staining information.

Can EasySep™ separations be automated?

Yes. RoboSep™, the fully automated cell separator, automates all EasySep™ labeling and cell separation steps.

Can EasySep™ be used to isolate rare cells?

Yes. We recommend a cell concentration of 2x10⁸ cells/mL and a minimum working volume of 100 µL. Samples containing 2x10⁷ cells or fewer should be suspended in 100 µL of buffer.

Are the EasySep™ magnetic particles FACS-compatible?

Yes, the EasySep™ particles are flow cytometry-compatible, as they are very uniform in size and about 5000X smaller than other commercially available magnetic beads used with column-free systems.

Can the EasySep™ magnetic particles be removed after enrichment?

No, but due to the small size of these particles, they will not interfere with downstream applications.

Can I alter the separation time in the magnet?

Yes; however, this may impact the kit's performance. The provided EasySep™ protocols have already been optimized to balance purity, recovery and time spent on the isolation.

For positive selection, can I perform more than 3 separations to increase purity?

Yes, the purity of targeted cells will increase with additional rounds of separations; however, cell recovery will decrease.

How does the binding of the EasySep™ magnetic particle affect the cells? is the function of positively selected cells altered by the bound particles?

Hundreds of publications have used cells selected with EasySep™ positive selection kits for functional studies. Our in-house experiments also confirm that selected cells are not functionally altered by the EasySep™ magnetic particles.

If particle binding is a key concern, we offer two options for negative selection. The EasySep™ negative selection kits can isolate untouched cells with comparable purities, while RosetteSep™ can isolate untouched cells directly from whole blood without using particles or magnets.

Regulatory Programs of B-cell Activation and Germinal Center Reaction Allow B-ALL Escape from CD19 CAR T-cell Therapy. N. G. Im et al. Cancer immunology research 2022 sep

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has led to tremendous successes in the treatment of B-cell malignancies. However, a large fraction of treated patients relapse, often with disease expressing reduced levels of the target antigen. Here, we report that exposing CD19+ B-cell acute lymphoblastic leukemia (B-ALL) cells to CD19 CAR T cells reduced CD19 expression within hours. Initially, CD19 CAR T cells caused clustering of CD19 at the T cell-leukemia cell interface followed by CD19 internalization and decreased CD19 surface expression on the B-ALL cells. CD19 expression was then repressed by transcriptional rewiring. Using single-cell RNA sequencing and single-cell assay for transposase-accessible chromatin using sequencing, we demonstrated that a subset of refractory CD19low cells sustained decreased CD19 expression through transcriptional programs of physiologic B-cell activation and germinal center reaction. Inhibiting B-cell activation programs with the Bruton's tyrosine kinase inhibitor ibrutinib increased the cytotoxicity of CD19 CAR T cells without affecting CAR T-cell viability. These results demonstrate transcriptional plasticity as an underlying mechanism of escape from CAR T cells and highlight the importance of combining CAR T-cell therapy with targeted therapies that aim to overcome this plasticity. See related Spotlight by Zhao and Melenhorst, p. 1040.

View publication

Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors. A. M. Metelo et al. Cancer research communications 2022 mar

Abstract

UNLABELLED Multiple myeloma remains an incurable plasma cell malignancy despite the rapidly evolving treatment landscape. Chimeric antigen receptor T cells targeted against BCMA have recently shown great promise in relapsed refractory multiple myeloma; however, all patients ultimately still progress from their disease. Lack of CAR T-cell persistence, impaired T-cell fitness in autologous CAR T-cell products and the presence of an immunosuppressive bone marrow (BM) microenvironment are contributory factors to treatment failure. We generated anti-BCMA CAR T cells from healthy donors (HD) and patients with multiple myeloma at different stages of disease to compare their T-cell profile, fitness, and cytotoxic activity in preclinical studies. We also used an ex vivo assay with multiple myeloma BM biopsies from distinct genomic subgroups to test the efficacy of HD-derived CAR T cells in a clinically relevant model. HD volunteers showed increased T-cell counts, higher CD4/CD8 ratio, and expanded na{\{i}}ve T-cell population compared with patients with multiple myeloma. After anti-BCMA CAR T-cell production patients with relapsed multiple myeloma had lower frequencies of CAR+ T cells decreased central memory phenotype and increased checkpoint inhibitory markers compared with HD-derived products which compromised their expansion and cytotoxicity against multiple myeloma cells in vitro. Importantly HD-derived CAR T cells efficiently killed primary multiple myeloma cells within the BM microenvironment of different multiple myeloma genomic subgroups and their cytotoxic activity could be boosted with gamma secretase inhibitors. In conclusion allogeneic anti-BCMA CAR T cells are a potential therapeutic strategy for patients with relapsed multiple myeloma and should be further developed in the clinic. SIGNIFICANCE Multiple myeloma is an incurable cancer of the plasma cells. A new therapy with anti-BCMA CAR T cells - the patient's own T cells genetically engineered to find and kill myeloma cancer cells - has shown encouraging results. Unfortunately patients still relapse. In this study we propose to use T cells from HD volunteers which have a stronger T-cell fitness higher cancer killing capacity and are ready to be administered when needed."

View publication

Impaired immunomodulatory effects of seminal plasma may play a role in unexplained recurrent pregnancy loss: Results of an in vitro study. N. A. du Foss\'e et al. Journal of reproductive immunology 2022 jun

Abstract

BACKGROUND Seminal plasma contains signaling molecules capable of modulating the maternal immune environment to support implantation and pregnancy. Prior studies indicated that seminal plasma induces changes in gene transcription of maternal immune cells. Reduced immune suppressive capacity may lead to pregnancy loss. The aim of this study was to investigate the immunomodulating effects of seminal plasma on T cells and monocytes in the context of recurrent pregnancy loss (RPL). METHODS Female T cells and monocytes were incubated with seminal plasma of 20 males in unexplained RPL couples (RPL males) and of 11 males whose partners had ongoing pregnancies (control males). The effect of seminal plasma on messenger RNA (mRNA) expression of immune cells was measured. Levels of mRNA expression were related to key signaling molecules present in the seminal plasma. Agglomerative hierarchical cluster analysis was performed on seminal plasma expression profiles and on mRNA expression profiles. RESULTS Expression of CD25 and anti-inflammatory IL-10 by female T cells was significantly lower after stimulation with seminal plasma of RPL males compared to control males. Female monocytes treated with seminal plasma of RPL males showed an immune activation signature of relatively elevated HLA-DR expression. Expression of these T cell and monocyte components was particularly correlated with the amounts of TGF-$\beta$ and VEGF in the seminal plasma. CONCLUSION Our findings indicate that seminal plasma has immunomodulating properties on female immune cells compatible with the induction of a more regulatory phenotype, which may be impaired in cases of unexplained RPL.

View publication

View All Publications

更多信息

更多信息
种属	Human
Magnet Compatibility	• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • Easy 50 EasySep™ Magnet (Catalog #18002) • EasyPlate™ EasySep™ Magnet (Catalog 18102) • EasyEights™ EasySep™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000)
样本来源	Leukapheresis, PBMC
Selection Method	Negative

标记抗体

抗人CD4抗体，克隆OKT4
小鼠单克隆IgG2b抗体，抗人、恒河猴、食蟹猴CD4
抗人CD8a抗体，克隆RPA-T8
小鼠单克隆IgG1抗体，抗人、恒河猴、食蟹猴CD8a
抗人CD3抗体，克隆UCHT1
小鼠（BALB/c）单克隆IgG1抗体，抗人、黑猩猩CD3

质量保证:

产品仅供研究使用，不用于针对人或动物的诊断或治疗。欲获悉更多关于STEMCELL的质控信息，请访问 STEMCELL.CN/COMPLIANCE.

Copyright © 2025 by STEMCELL Technologies. All rights reserved.